CYTOKINETICS, INCORPORATED (CYTK) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $27.36M; Long-term Debt, Excluding Current MaturitiesUSD $248.20M; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $44.81M; Long-term Debt, Excluding Current MaturitiesUSD $247.21M; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $41.18M; Long-term Debt, Excluding Current MaturitiesUSD $246.38M; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD $37.96M.
CYTOKINETICS, INCORPORATED Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Face Amount USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Secured Debt, Current USD | Long-term Line of Credit USD | Line of Credit Facility, Maximum Amount Outstanding During Period USD | Line of Credit Facility, Current Borrowing Capacity USD | Long-term Debt, Fair Value USD | Debt Instrument, Unamortized Discount USD | Debt Instrument, Interest Rate, Effective Percentage Rate Range, Maximum (Deprecated 2016-01-31) pure | Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum (Deprecated 2016-01-31) pure | Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $27.36M | $248.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $44.81M | $247.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $41.18M | $246.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | $37.96M | $158.57M | $13.12M | $13.12M | $13.12M | $763.12M | (m) | $999.04M | $911.66M | $21.04M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $17.28M | $158.75M | $1.00B | $40.42M | $158.57M | $13.12M | $13.12M | (m) | $776.25M | $423.00K | (m) | $911.66M | $22.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $14.40M | $159.06M | $609.65M | $40.88M | $558.90M | (m) | (m) | (m) | (m) | $9.87M | (m) | $561.13M | $7.15M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $12.96M | $92.03M | $610.07M | $40.88M | $558.90M | (m) | (m) | (m) | (m) | $10.29M | (m) | $561.13M | $7.99M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $11.52M | $93.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $619.52M | $19.75M | $40.88M | $558.90M | (m) | (m) | (m) | (m) | (m) | $561.13M | $8.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $11.52M | $93.02M | $619.95M | $19.75M | $40.88M | $558.90M | (m) | (m) | (m) | $423.00K | (m) | $561.13M | $9.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $11.52M | $92.83M | $629.40M | $19.75M | $40.88M | $558.90M | (m) | (m) | (m) | $9.87M | (m) | $561.13M | $10.53M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $11.52M | $56.82M | $629.82M | $19.75M | $40.88M | $558.90M | (m) | (m) | (m) | $10.29M | (m) | $561.13M | $11.34M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $10.08M | $58.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $639.27M | $19.75M | $19.75M | $40.88M | $558.90M | (m) | (m) | (m) | (m) | $561.13M | $12.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $60.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $62.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $64.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $958.00K | $63.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $649.56M | $10.29M | $19.75M | $19.75M | $40.88M | $558.90M | (m) | (m) | (m) | $561.13M | $15.32M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $63.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $62.34M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $61.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $47.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $47.40M | (m) | (m) | (m) | (m) |
| 2021-09-30 | $16.88M | $30.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $47.10M | (m) | (m) | (m) | (m) |
| 2021-06-30 | $11.25M | $35.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $46.80M | (m) | (m) | (m) | (m) |
| 2021-03-31 | $5.62M | $40.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $46.50M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $46.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $46.20M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $45.92M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $45.90M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $45.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $45.60M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $45.34M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $45.30M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $45.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $45.10M | (m) | (m) | (m) | (m) |
| 2019-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $0.00 | $44.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $44.80M | (m) | (m) | (m) | (m) |
| 2019-06-30 | $0.00 | $44.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $44.50M | (m) | (m) | (m) | (m) |
| 2019-03-31 | $6.21M | $36.38M | $42.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $42.00M | (m) | (m) | (m) | (m) | (m) | (m) | $42.60M | (m) | (m) | (m) | (m) |
| 2018-12-31 | $2.61M | $39.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $42.40M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $42.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $42.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $3.78M | $38.13M | $41.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $42.00M | (m) | (m) | (m) | (m) | (m) | (m) | $41.90M | $496.00K | (m) | (m) | (m) |
| 2018-06-30 | $1.70M | $30.66M | $32.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $32.00M | (m) | (m) | (m) | (m) | (m) | (m) | $32.40M | $41.00K | (m) | (m) | (m) |
| 2018-03-31 | $0.00 | $31.95M | $31.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $32.00M | (m) | (m) | (m) | (m) | (m) | (m) | $32.00M | $300.00K | (m) | (m) | (m) |
| 2017-12-31 | $0.00 | $31.78M | $31.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $32.00M | (m) | (m) | (m) | (m) | (m) | (m) | $31.80M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $325.00K | (m) | (m) | (m) |
| 2017-09-30 | $9.83M | $20.47M | $30.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | $30.30M | $322.00K | (m) | (m) | (m) |
| 2017-06-30 | $7.32M | $22.84M | $30.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | $30.00M | $372.00K | (m) | (m) | (m) |
| 2017-03-31 | $4.83M | $25.20M | $30.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | $30.00M | $422.00K | (m) | (m) | (m) |
| 2016-12-31 | $2.50M | $27.38M | $29.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | $29.90M | $472.00K | (m) | (m) | (m) |
| 2016-09-30 | (m) | $29.74M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $522.00K | (m) | (m) | (m) |
| 2016-06-30 | (m) | $29.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $571.00K | (m) | (m) | (m) |
| 2016-03-31 | (m) | $29.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) | $29.50M | $620.00K | (m) | (m) | (m) |
| 2015-12-31 | $0.00 | $14.64M | $14.64M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $15.00M | (m) | (m) | (m) | (m) | (m) | (m) | $14.60M | $-389.00K | (m) | (m) | (m) |
| 2014-12-31 | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | $0.00 | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $152.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $152.00K |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $152.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $310.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $489.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $833.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $4.10M | (m) | (m) | (m) | 12 month · 7.68% | 12 month · 7.24% | (m) |
| 2006-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $4.10M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2006-04-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.60M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |